• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by InflaRx N.V.

    2/18/25 4:11:01 PM ET
    $IFRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $IFRX alert in real time by email
    6-K 1 ny20043420x3_6k.htm FORM 6-K

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549



    FORM 6-K
     

    Report of Foreign Private Issuer
    Pursuant to Rule 13a-16 or 15d-16
    of the Securities Exchange Act of 1934
    For the month of February 2025
    Commission File Number: 001-38283
     

    InflaRx N.V.
    (Translation of registrant’s name into English)
     

    Winzerlaer Str. 2
    07745 Jena, Germany
    (Address of Principal Executive Offices)
     

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
     
    Form 20-F ☒ Form 40-F ☐



    INFLARX N.V.
     
    On February 13, 2025, InflaRx N.V. (the “Company”) entered into an Underwriting Agreement with Guggenheim Securities, LLC, as representative of the several underwriters (the “Underwriters”) named in Schedule 1 therein, relating to the offering (the “Offering”) of an aggregate of 8,250,000 ordinary shares (“Firm Shares”), nominal value €0.12 per share (the “Ordinary Shares”), of the Company and pre-funded warrants to purchase 6,750,000 Ordinary Shares (the “Pre-Funded Warrants”). The Offering closed on February 18, 2025.
     
    The public offering price for the Ordinary Shares was $2.00 per share. The public offering price for each Pre-Funded Warrant was equal to the price per share at which the Ordinary Shares were sold to the public, minus $0.001, which is the exercise price of each Pre-Funded Warrant. The Pre-Funded Warrants are exercisable at any time until fully exercised, subject to an ownership limitation, as set forth in the form of Pre-Funded Warrant. In addition, the Company granted the Underwriters a 30-day option to purchase up to an additional 2,250,000 Ordinary Shares (the “Option Shares” and, together with the Firm Shares, the “Shares”).
     
    The gross proceeds from the Offering were approximately $30 million, or will be approximately $34.5 million if the Underwriters exercise in full their option to purchase the Option Shares, before deducting the underwriting discount and estimated offering expenses.
     
    The Offering was made pursuant to the Company’s effective shelf registration statement on Form F-3 (File No. 333-273058), which was previously filed with the U.S. Securities and Exchange Commission, and a prospectus supplement, dated February 13, 2025, and the accompanying prospectus, dated July 11, 2023.
     
    The Underwriting Agreement contains customary representations, warranties and agreements by the Company. Additionally, the Company has agreed to indemnify the Underwriters against certain liabilities, including liabilities under the Securities Act of 1933, as amended, or to contribute to payments the Underwriters may be required to make because of any of those liabilities.
     
    The foregoing description of the Underwriting Agreement is qualified in its entirety by reference to the complete text of the Underwriting Agreement, a copy of which is filed herewith as Exhibit 1.1 and is incorporated herein by reference.
     
    The foregoing description of the Pre-Funded Warrant is qualified in its entirety by reference to the complete text of the form of Pre-Funded Warrant, a copy of which is filed herewith as Exhibit 4.1 and is incorporated herein by reference.
     
    A copy of the opinion of NautaDutilh N.V. relating to the legality of the issuance and sale of the Shares is attached as Exhibit 5.1. A copy of the opinion of Kirkland & Ellis LLP relating to the legality of the issuance and sale of the Pre-Funded Warrants is attached as Exhibit 5.2.
     
    INCORPORATION BY REFERENCE
     
    This report on Form 6-K, including Exhibits 1.1, 4.1, 5.1 and 5.2, shall be deemed to be incorporated by reference into (i) the Company’s registration statements on Form S-8 (File No. 333-221656 and 333-240185) and (ii) the Company’s registration statement on Form F-3 (File No. 333-273058) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.


    EXHIBIT INDEX
     
    Exhibit No.
    Description
       
    1.1
    Underwriting Agreement, dated as of February 13, 2025, between InflaRx N.V. and Guggenheim Securities, LLC, as representative of the underwriters named in Schedule 1 therein
       
    4.1
    Form of Pre-Funded Warrant
       
    5.1
    Opinion of Nauta Dutilh N.V.
       
    5.2
    Opinion of Kirkland & Ellis LLP
       
    23.1
    Consent of Nauta Dutilh N.V. (included in Exhibit 5.1)
       
    23.2
    Consent of Kirkland & Ellis LLP (included in Exhibit 5.2)


    SIGNATURES
     
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     
    INFLARX N.V.
     
           
    Date: February 18, 2025
    By:
    /s/ Niels Riedemann
     
     
    Name:
    Niels Riedemann
     
     
    Title:
    Chief Executive Officer
     



    Get the next $IFRX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $IFRX

    DatePrice TargetRatingAnalyst
    5/29/2025$2.00Strong Buy → Outperform
    Raymond James
    4/29/2025$10.00Overweight
    Cantor Fitzgerald
    4/5/2023$8.00Neutral → Buy
    Guggenheim
    2/28/2022Buy → Neutral
    Guggenheim
    11/8/2021$14.00 → $15.00Strong Buy
    Raymond James
    10/28/2021$14.00Outperform → Strong Buy
    Raymond James
    8/6/2021$11.00 → $10.00Outperform
    Raymond James
    8/6/2021$2.80 → $2.50Underperform
    Credit Suisse
    More analyst ratings

    $IFRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    InflaRx downgraded by Raymond James with a new price target

    Raymond James downgraded InflaRx from Strong Buy to Outperform and set a new price target of $2.00

    5/29/25 8:15:13 AM ET
    $IFRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cantor Fitzgerald initiated coverage on InflaRx with a new price target

    Cantor Fitzgerald initiated coverage of InflaRx with a rating of Overweight and set a new price target of $10.00

    4/29/25 8:10:45 AM ET
    $IFRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    InflaRx upgraded by Guggenheim with a new price target

    Guggenheim upgraded InflaRx from Neutral to Buy and set a new price target of $8.00

    4/5/23 11:33:25 AM ET
    $IFRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IFRX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    InflaRx Announces Participation in September Investor Conferences

    JENA, Germany, Aug. 21, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (NASDAQ:IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced it will participate in two investor conferences in September 2025. Details are as follows: Cantor Global Healthcare Conference 2025September 3 - 5, 2025 in New York, NYFireside chat on September 4th at 9:10 AM ET InflaRx will also conduct one-on-one investor meetings on September 4th. A link to view the fireside chat live stream and its replay is available here. H.C. Wainwright 27th Annual Global Investment ConferenceSeptember 8 - 10, 2025 in New York, NYPresentation on September 9th at 3:30

    8/21/25 7:30:00 AM ET
    $IFRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    InflaRx Reports Second Quarter 2025 Financial Results and Provides Business Update

    INF904 Phase 2a data in chronic spontaneous urticaria (CSU) and hidradenitis suppurativa (HS) expected by the end of September to early November 2025Phase 1/2 data announced by Staidson BioPharmaceuticals for InflaRx-partnered C5a antibody BDB-001 in ANCA-associated vasculitis (AAV) were favorable, with Staidson expecting Phase 3 study initiationInflaRx working diligently toward unblinding of stopped Phase 3 pyoderma gangrenosum (PG) trial so that all data can be analyzed later this yearEnrollment began in BARDA funded JUST BREATHE Phase 2 platform clinical trial investigating vilobelimab and additional novel therapeutic candidates for acute respiratory distress syndrome (ARDS)Cash, cash equ

    8/7/25 7:30:00 AM ET
    $IFRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    InflaRx to Report Second Quarter 2025 Results on August 7, 2025

    JENA, Germany, July 31, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (NASDAQ:IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that the Company will report its second quarter 2025 financial and operating results on August 7, 2025, before the market opens. No conference call is planned. About InflaRx InflaRx (NASDAQ:IFRX) is a biopharmaceutical company pioneering anti-inflammatory therapeutics by applying its proprietary anti-C5a and anti-C5a receptor technologies to discover, develop and commercialize highly potent and specific inhibitors of the complement activation factor C5a and its receptor. C5a is a powe

    7/31/25 7:30:00 AM ET
    $IFRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IFRX
    SEC Filings

    View All

    SEC Form 6-K filed by InflaRx N.V.

    6-K - InflaRx N.V. (0001708688) (Filer)

    8/7/25 8:12:58 AM ET
    $IFRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by InflaRx N.V.

    6-K - InflaRx N.V. (0001708688) (Filer)

    7/14/25 4:15:19 PM ET
    $IFRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by InflaRx N.V.

    6-K - InflaRx N.V. (0001708688) (Filer)

    6/27/25 4:05:32 PM ET
    $IFRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IFRX
    Leadership Updates

    Live Leadership Updates

    View All

    InflaRx Appoints Jan Medina as Head of Investor Relations

    JENA, Germany, Feb. 22, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (NASDAQ:IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced the appointment of Jan Medina, CFA, as Vice President and Head of Investor Relations of InflaRx. Mr. Medina brings over 25 years of extensive experience across the life sciences sector and capital markets, including in the areas of investor relations, communications and equity research. Prof. Niels C. Riedemann, Chief Executive Officer and Founder of InflaRx, said: "We are delighted to welcome Jan to our team. His experience, proven track record and deep network with investors and capital mark

    2/22/24 7:30:00 AM ET
    $IFRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    InflaRx Appoints Dr. Camilla Chong as Chief Medical Officer

    Camilla Chong, M.D., joins the team with 25 years of experience in the global pharmaceutical industry in drug developmentDr. Chong to lead clinical development of InflaRx's portfolio of C5a/C5aR inhibitors JENA, Germany, June 28, 2023 (GLOBE NEWSWIRE) -- InflaRx N.V. (NASDAQ:IFRX), a clinical-stage biopharmaceutical company commercializing and developing anti-inflammatory therapeutics that target the complement system, today announced the appointment of Dr. Camilla Chong as Chief Medical Officer (CMO) of InflaRx, effective July 1, 2023. Dr. Chong is a medical doctor with extensive experience in the pharmaceutical industry, including leadership roles in clinical development, medical affai

    6/28/23 7:30:00 AM ET
    $IFRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IFRX
    Financials

    Live finance-specific insights

    View All

    InflaRx to Report Second Quarter 2025 Results on August 7, 2025

    JENA, Germany, July 31, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (NASDAQ:IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that the Company will report its second quarter 2025 financial and operating results on August 7, 2025, before the market opens. No conference call is planned. About InflaRx InflaRx (NASDAQ:IFRX) is a biopharmaceutical company pioneering anti-inflammatory therapeutics by applying its proprietary anti-C5a and anti-C5a receptor technologies to discover, develop and commercialize highly potent and specific inhibitors of the complement activation factor C5a and its receptor. C5a is a powe

    7/31/25 7:30:00 AM ET
    $IFRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    InflaRx to Report First Quarter 2025 Results on May 7, 2025

    JENA, Germany, April 30, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (NASDAQ:IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that it will report its first quarter 2025 financial and operating results on May 7, 2025, before the market opens. No conference call is planned. About InflaRx InflaRx (NASDAQ:IFRX) is a biopharmaceutical company pioneering anti-inflammatory therapeutics by applying its proprietary anti-C5a and anti-C5aR technologies to discover, develop and commercialize highly potent and specific inhibitors of the complement activation factor C5a and its receptor C5aR. C5a is a powerful inflammatory media

    4/30/25 7:30:00 AM ET
    $IFRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    InflaRx to Report Full Year 2024 Results on March 20 and Announces Participation in March Investor Conferences

    JENA, Germany, Feb. 25, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (NASDAQ:IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that the Company will publish its financial and operating results for the fourth quarter and full year 2024 on March 20, 2025; no conference call is planned. InflaRx also announced that it will participate in two investor conferences. Details are as follows: Leerink Global Healthcare ConferenceMarch 9 - 12, 2025 in Miami Beach, FL InflaRx will conduct a fireside chat at the conference on March 10 at 10:40 AM ET and will participate in one-on-one-investor meetings. A link to regis

    2/25/25 7:30:00 AM ET
    $IFRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IFRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by InflaRx N.V.

    SC 13G - InflaRx N.V. (0001708688) (Subject)

    4/24/23 4:47:08 PM ET
    $IFRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by InflaRx N.V.

    SC 13G - InflaRx N.V. (0001708688) (Subject)

    4/17/23 4:00:10 PM ET
    $IFRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by InflaRx N.V. (Amendment)

    SC 13G/A - InflaRx N.V. (0001708688) (Subject)

    2/13/23 12:01:42 PM ET
    $IFRX
    Biotechnology: Pharmaceutical Preparations
    Health Care